相关实验视频

Updated: Sep 19, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

一个CMTM6纳米体克服了非小细胞肺癌中的EGFR-TKI抵抗

Lu Xia¹, Jichuan Wang², Hui Xue³

¹Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing, 100191, China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|June 16, 2025

概括

化基因类跨膜蛋白6 (CMTM6) 在非小细胞肺癌 (NSCLC) 中稳定表皮生长因子受体 (EGFR). 向CMTM6可以克服NSCLC患者对氨酸激酶抑制剂 (TKI) 治疗的耐药性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

异常的表皮生长因子受体 (EGFR) 信号驱动非小细胞肺癌 (NSCLC) 的发展.
氨酸激酶抑制剂 (TKI) 疗法对NSCLC有效,但耐药性仍然是一个重大的临床挑战.

研究的目的:

调查化学类跨膜蛋白6 (CMTM6) 在EGFR调节中的作用及其作为NSCLC治疗点的潜力.
确定是否针对CMTM6-EGFR相互作用可以克服NSCLC中的TKI抵抗.

主要方法:

同免疫沉以评估CMTM6-EGFR相互作用.
免疫光显微镜分析CMTM6,EGFR和RAB11在NSCLC细胞和瘤中的同位化.
在体外和体内异种移植模型中开发和测试一种向CMTM6的纳米体.

主要成果:

CMTM6在RAB11阳性循环内体中与EGFR物理结合和同定位,防止EGFR的溶解体降解.
在NSCLC中CMTM6表达升高与预后不佳和CMTM6-EGFR-RAB11同局部增强相关.
一个向CMTM6的纳米体阻断了CMTM6-EGFR的相互作用,降低了EGFR水平,并抑制了TKI抵抗性NSCLC细胞的增殖和瘤生长.

结论:

CMTM6通过调节其内细胞流通,作为EGFR稳定剂.
向CMTM6是一种有希望的治疗策略,可以克服NSCLC中的EGFR-TKI耐药性.

关键词:

在CMTM6中,CMTM6是CMTM6.欧洲农业基金会 (EGFR) 是一个.对于EGFR-TKIs的耐药性问题.在NSCLCLC中,我们可以看到NSCLCLC.纳米体是一个纳米体.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...